GTBPGT Biopharma, Inc.

Nasdaq gtbiopharma.com


$ 2.05 $ -0.11 (-5.34 %)    

Friday, 06-Sep-2024 15:57:55 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 1.95
$ 1.95 x 200
-- x --
-- - --
$ 1.95 - $ 10.66
13,662
na
4.36M
$ 0.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-01-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 10-31-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-23-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 04-16-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-27-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 03-29-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 04-28-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-10-2016 06-30-2016 10-Q
34 05-13-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-31-2015 12-31-2014 10-K
40 01-08-2015 12-31-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-q2-eps-217-down-from-149-yoy

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(2.17) per share. This is a 45.64 percent decrease over losses of $(1....

 gt-biopharma-announces-fda-clearance-for-gtb-3650-ind-application-phase-1-trial-to-begin-in-h2-2024-with-initial-data-expected-in-h1-2025

GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission ...

 whats-going-on-with-gt-biopharma-stock-tuesday

GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common ...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/21/2024 13:39:14

 whats-going-on-with-gt-biopharma-stock

GT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top tre...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/20/2024 13:53:48

 gt-biopharma-q1-eps-164-beats-270-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of $(2.70) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION